Amazon.com, Inc. (AMZN)
Latest news, insights and market data
Market Data
AI Insights
Amazon is stepping into the GLP-1 obesity and diabetes treatment space, competing with Eli Lilly's Foundayo. This move highlights Amazon's strategy to diversify its offerings beyond e-commerce, positioning itself in the growing healthcare market. The entry could intensify competition and reshape dynamics in the obesity treatment sector.
Latest News
| Title | Published |
|---|---|
The Best Stocks to Buy With $10,000 Right Now These three stocks have solid catalysts ahead. | about 7 hours ago |
The USPS Got a ‘Free Lunch’ for Decades. That’s Over Now On a recent episode of NerdWallet’s Smart Money Podcast titled USPS’ Cash Crisis Hits More Than Your Mailbox, Plus The Debt Settlement Trap to Avoid, the guest framed the U.S. Postal Service’s predicament in economist’s terms: “I like to describe it as there is no free lunch. Economists love to say that, but for a ... The USPS Got a ‘Free Lunch’ for Decades. That’s Over Now | about 8 hours ago |
Stock Market Week Ahead: Hyperscaler Blitz, Federal Reserve Transition The stock market brims with optimism ahead of a huge surge of AI hyperscaler earnings, amid an historical transition at the Federal Reserve. | about 8 hours ago |
Want Safe Income While the Market Wobbles? Buy This Dividend Stock With $5,000. TJX stock provides a combination of income and market-beating growth. | about 9 hours ago |
Foundayo’s Slow Start And Amazon Entry Test Eli Lilly Valuation Eli Lilly’s new oral obesity pill, Foundayo, is seeing slower initial prescription uptake than early expectations in its first weeks on the market. Recent data suggests Foundayo’s launch trails the early momentum seen in Novo Nordisk’s oral Wegovy pill. Amazon has entered the GLP-1 obesity and diabetes treatment space with a clinical and pharmacy program, adding fresh competition. Eli Lilly (NYSE:LLY) is coming into this news after a sharp multiyear share price run, with the stock up about... | about 10 hours ago |
Is the AI Gold Rush Still On? A Historical Look at Amazon's AWS Offers a Compellingly Clear Answer. Amazon has been one of the early AI winners. | about 10 hours ago |
Meet the Biggest Threat to Nvidia in AI Chips. It's Not AMD, Intel, or Broadcom. Alphabet is enjoying strong demand for the AI processors it designed in-house. | about 11 hours ago |
The Best Stocks to Buy With $10,000 Right Now
These three stocks have solid catalysts ahead.
The USPS Got a ‘Free Lunch’ for Decades. That’s Over Now
On a recent episode of NerdWallet’s Smart Money Podcast titled USPS’ Cash Crisis Hits More Than Your Mailbox, Plus The Debt Settlement Trap to Avoid, the guest framed the U.S. Postal Service’s predicament in economist’s terms: “I like to describe it as there is no free lunch. Economists love to say that, but for a ... The USPS Got a ‘Free Lunch’ for Decades. That’s Over Now
Stock Market Week Ahead: Hyperscaler Blitz, Federal Reserve Transition
The stock market brims with optimism ahead of a huge surge of AI hyperscaler earnings, amid an historical transition at the Federal Reserve.
Want Safe Income While the Market Wobbles? Buy This Dividend Stock With $5,000.
TJX stock provides a combination of income and market-beating growth.
Foundayo’s Slow Start And Amazon Entry Test Eli Lilly Valuation
Eli Lilly’s new oral obesity pill, Foundayo, is seeing slower initial prescription uptake than early expectations in its first weeks on the market. Recent data suggests Foundayo’s launch trails the early momentum seen in Novo Nordisk’s oral Wegovy pill. Amazon has entered the GLP-1 obesity and diabetes treatment space with a clinical and pharmacy program, adding fresh competition. Eli Lilly (NYSE:LLY) is coming into this news after a sharp multiyear share price run, with the stock up about...
Is the AI Gold Rush Still On? A Historical Look at Amazon's AWS Offers a Compellingly Clear Answer.
Amazon has been one of the early AI winners.
Meet the Biggest Threat to Nvidia in AI Chips. It's Not AMD, Intel, or Broadcom.
Alphabet is enjoying strong demand for the AI processors it designed in-house.